Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. 1996

J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
Biology Division, National Cancer Center Research Institute, Tokyo, Japan.

Multiple genetic alterations, including inactivation of the p53 and RB genes and loss of heterozygosity on chromosome 3p, occur commonly in small cell lung carcinoma (SCLC). To assess the biological significance of p53 inactivation in the development of SCLC, tetracycline (Tc)-inducible p53 expression plasmids were introduced into a SCLC cell line, N417, in which the p53 gene as well as the RB gene was inactivated. In the absence (induced) of Tc, cells transfected with the wild-type p53 gene formed colonies in 29-58% of those with a mutant p53 gene. However, wild-type p53 genes were expressed in 0 of 43 transfectants, whereas mutant p53 genes were expressed in 75% (36/48) of the transfectants, suggesting that the growth of SCLC cells was suppressed by the expression of the wild-type p53 gene. Thus, wild-type p53-inducible clones were further established by transfection in the presence (repressed) of Tc. The in vitro growth was significantly suppressed by the induction of wild-type p53 expression, and apoptosis but not G1 arrest was observed within 24 h of p53 induction. These results strongly suggest that the restoration of the p53 function is sufficient to suppress the growth of SCLC cells in which other genetic alterations remain uncorrected, and that growth suppression by p53 is due to induction of apoptosis but not due to induction of G1 arrest through the RB pathway.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53
D016193 G1 Phase The period of the CELL CYCLE preceding DNA REPLICATION in S PHASE. Subphases of G1 include "competence" (to respond to growth factors), G1a (entry into G1), G1b (progression), and G1c (assembly). Progression through the G1 subphases is effected by limiting growth factors, nutrients, or inhibitors. First Gap Phase,G1a Phase,G1b Phase,Gap Phase 1,First Gap Phases,G1 Phases,G1a Phases,G1b Phases,Gap Phase, First,Gap Phases, First,Phase 1, Gap,Phase, First Gap,Phase, G1,Phase, G1a,Phase, G1b,Phases, First Gap,Phases, G1,Phases, G1a,Phases, G1b
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D018014 Gene Transfer Techniques The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms. Gene Delivery Systems,Gene Transfer Technique,Transgenesis,Delivery System, Gene,Delivery Systems, Gene,Gene Delivery System,Technique, Gene Transfer,Techniques, Gene Transfer,Transfer Technique, Gene,Transfer Techniques, Gene
D018288 Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7) Carcinoma, Oat Cell,Oat Cell Carcinoma,Small Cell Carcinoma,Carcinomas, Oat Cell,Carcinomas, Small Cell,Oat Cell Carcinomas,Small Cell Carcinomas

Related Publications

J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
December 1996, Molecular endocrinology (Baltimore, Md.),
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
September 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
February 2001, International journal of radiation biology,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
November 1995, Molecular and cellular biology,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
January 1996, Zhonghua er bi yan hou ke za zhi,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
November 1999, International journal of oncology,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
May 2017, Marine drugs,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
July 1995, Cancer research,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
August 2001, Molecules and cells,
J Adachi, and K Ookawa, and M Shiseki, and T Okazaki, and S Tsuchida, and K Morishita, and J Yokota
March 2005, Cell cycle (Georgetown, Tex.),
Copied contents to your clipboard!